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Abstract The Jak kinases and Stat transcription factors play 
a major role in signaling of various cytokines including IFNa. In 
this report we show a ligand-independent interaction between 
Tyk-2 and Jak-I kinases. We also demonstrate that the Tyk-2 
kinase forms a homodimer that has the ability to undergo inter- 
molecular tyrosine phosphorylation. The formation of the Tyk-2 
homodimer is independent of both tyrosine phosphorylation and 
the presence of the tyrosine kinase domain. 
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1. Introduction 
Tyrosine phosphorylation plays a central role in signaling by 
different cytokine and growth factors including type I interfer- 
ons (IFNs). Type I IFNs (IFN~/fl/oJ) bind to a cell surface 
receptor (IFN~R or type I IFN-R) composed of two chains: 
the ~ and fl subunits [1-3]. The ~ subunit corresponds to the 
cDNA termed IFNAR cloned by Uz6 et al. [4,5]. The IFNc~flR 
cDNA recently cloned by Novick et al. [6] corresponds to a 
short form of the fl subunit (termed fls), while a long form 
(termed ilL) has been recently cloned in our laboratory and is 
reported elsewhere [7]. The cytoplasmic domain of the ~ sub- 
unit directly associates with Tyk-2 [5,8]. Similarly, Jak-I ap- 
pears to coprecipitate with the 1~ subunit [6], although a direct 
interaction has not been demonstrated. Type I IFN binding to 
the receptor induces rapid tyrosine phosphorylation f the Tyk- 
2 [5,9] and Jak-1 kinases [9-11], the components of the tran- 
scription factor ISGF3t (Statle, Statlfl, and Stat2) [12-16] (re- 
viewed in [17]), and the ~ and ]3 subunits ofthe IFNczR [18-20], 
(E.N. Constantinescu et al., Proc. Natl. Acad. Sci. USA 91 
(1994) 9602-9606). 
Genetic complementation studies have had a cornerstone 
role in elucidating the first steps of the type I IFN signaling 
pathway [9,21,22]. It has been demonstrated that expression of 
the Jak-1 kinase in mutant U4 cells restores the IFNy and 
IFNcz responses indicating that Jak-1 plays a role in signaling 
by IFNcz and IFNz [9]. A different mutant cell line, U1D which 
lacks the expression of Tyk-2, fails to phosphorylate Jak-I in 
response to IFN~ indicating that these kinases are interdepend- 
ent [9]. Interestingly, both U4 and U1D mutant cells showed 
impaired IFN~ binding ability indicating that Tyk-2 and Jak-1 
must play a role in the assembly of the IFN~R [9,23]. Velazquez 
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et al. [23] have demonstrated that mutant U1D cells bind IFNc~ 
with low affinity, and that transfection of Tyk-2 restores high 
affinity binding. The low affinity binding observed in U 1D cells 
[23] resembles the low affinity receptors observed in mouse 
transfectants that only express the human fl subunit of the type 
I IFN-R [7]. These findings led us to hypothesize that an inter- 
action, either direct or through adapter proteins, between the 
Tyk-2 and Jak-1 kinases brings together the ~ and fl subunits 
to form the high affinity receptor. In this report we demonstrate 
that: (i) there is an interaction between the Jak-1 and Tyk-2 
kinases; (ii) this interaction does not appear to require tyrosine 
phosphorylation f the kinases; and (iii) the Tyk-2 kinase forms 
a homodimer that can undergo intermolecular tyrosine phos- 
phorylation. 
2. Materials and methods 
2.1. IFNs and antibodies 
Human recombinant IFNc~2 was kindly provided by Dr.M. Brunda 
(Hoffman-La Roche). The antiphosphotyrosine and a ti-JAK-I anti- 
bodies were obtained from UBI (Lake Placid, NY) and the anti-tyk2 
monoclonal antibody was purchased from Transduction Laboratories. 
The rabbit sera anti-Tyk2 have been previously described [8]. 
2.2. Immunoblotting 
Cells were treated as indicated or left untreated, rapidly centrifuged 
at 2000 x g for 30 s in an Eppendorf microfuge, and subsequently 
solubilized in lysis buffer (1% Triton X-100/150 mM NaCl/25 mM 
HEPES (pH 7.5)/1 mM EDTAJ200/~M sodium orthovanadate/100 mM 
NaF/1 mM MgCI2/I mM phenyl methylsulfonyl fluoride/10 gtg/ml 
aprotinin/10/tg/ml leupeptin) at 4°C for 30 min. Protein complexes 
were precipitated from cell lysates with the indicated antibodies and 
protein-G Sepharose (Pharmacia). The immunoprecipitates were ana- 
lyzed by SDS-PAGE, and transferred to polyvinyldenedilfluoride filters 
(Immobilon, Millipore). Non-specific binding sites on th  filter were 
blocked with 10 mM Tris, pH 8.0, 150 mM NaC1, 0.05% Tween 20 
containing 5-8% bovine serum albumin for 1 h at room temperature. 
Immunoblots were subsequently incubated with the indicated primary 
antibodies and appropriate secondary antibodies (linked to horseradish 
peroxidase) and developed using an enhanced chemiluminescence kit 
(Amersham). 
2.3. Expression f Jak kinases using the vaccinia virus/T7 polymerase 
system 
The cDNAs encoding the different constructs for the Tyk-2 and 
Jak-1 kinases were subcloned into the pGem vector under th  control 
of the T7 promoter. Cos 7 cells were infected with vaccinia virus carry- 
ing the T7 polymerase gene as pr viously reported [24]. Thirty minutes 
after infection, cell were transfected using the lipofectamine reagent 
(Gibco-BRL) following manufacturers' procedures, an  incubate for 16 
h at 37°C. Cells were lysed as described above for the immunoblotting 
procedure. 
3. Results and discussion 
3.1. Interaction between Jak-1 and Tyk-2 
To look for an interaction between the Tyk-2 and Jak-1 
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tyrosine kinases we first performed coprecipitation experiments 
using Hela cells that have been treated with IFN~2 or left 
untreated. Fig. 1A (upper panel) shows that the Tyk-2 C-termi- 
nal serum coprecipitates a protein that comigrates with Jak-1 
in anti-Jak-1 immunoblots. Similarly, stripping and reprobing 
of the same filter with an anti-Tyk-2 antibody showed that the 
anti-Jak-1 serum coprecipitates Tyk-2 (Fig. 1A, lower panel). 
These results suggests that there may be a ligand independent 
interaction of the Jak-1 and Tyk-2 kinases. 
Since the stoichiometry of the Tyk-2/Jak-1 interaction was 
fractional, we sought an independent way to demonstrate he 
interaction between these Jak kinases. We overexpressed the 
Jak tyrosine kinases, alone or in combination, using the vac- 
cinia virus system. The Jak-1 and Tyk-2 cDNAs were sub- 
cloned into the pGEM vector under the control of the T7 
promoter, and were transfected into COS7 cells that had been 
previously infected with a vaccinia virus strain carrying the T7 
polymerase gene [24]. Cell lysates were immunoprecipitated 
with the different anti-Jak kinase antibodies followed by im- 
munoblotting with an anti-phosphotyrosine monoclonal anti- 
body. We selected immunoblotting with antiphosphotyrosine 
antibodies because th transiently overexpressed Jak kinases 
are baseline tyrosine phosphorylated [5,8,10,25] allowing us to 
discriminate the recombinant protein from the non-phosphor- 
ylated endogenous kinases. More over, tyrosine phosphoryla- 
tion of the endogenous Jak kinases resulting from type I IFNs 
in the conditioned medium of vaccinia virus infected cells is not 
possible, as vaccinia virus produces the B 18R protein that binds 
IFNs and completely blocks IFNc~ signaling [26]. Fig. 1B shows 
that the anti-Tyk-2 and anti-Jak-1 sera coprecipitate tyrosine 
phosphorylated Jak-1 and Tyk-2, respectively, in COS 7 cells 
cotransfected with the wild type Jak-1 and Tyk-2 constructs. 
Furthermore, overexpression of only the Tyk-2 kinase shows 
that the recombinant Tyk-2 protein interacts with the en- 
dogenous (non-phosphorylated) Jak-I protein as it can be 
coprecipitated by the anti-Jak-1 serum (Fig. 1B). Similarly, the 
overexpressed Jak-1 kinase interacts with the endogenous Tyk- 
2 protein (Fig. 1B). Immunoprecipitation with an anti-Jak-2 
serum also shows coprecipitation of tyrosine phosphorylated 
Jak-1, indicating that Jak-1 may also interact with the Jak-2 
tyrosine kinases. 
3.2. Tyrosine kinase activity of Tyk-2 is not required for 
association with Jak-1 
The experiments performed with Hela cells (Fig. 1A) sug- 
gested that the interaction between the Jak- 1 and Tyk-2 kinases 
does not require tyrosine phosphorylation, as it is detected in 
the absence of IFNc~2 treatment. To demonstrate hat tyrosine 
kinase activity of Tyk-2 is not necessary for interaction with 
Jak-1, we coexpressed the tyrosine kinase deficient mutant 
Tyk2(K930I) [8] with the wild type Jak-1 tyrosine kinase. Fig. 
1C shows that no tyrosine phosphorylation f the mutant Tyk- 
2 is observed when Tyk-2(K930I) is expressed alone. However, 
the anti-Tyk-2 serum coprecipitates tyrosine phosphorylated 
Jak-1 when the wild type Jak-1 kinase is coexpressed with the 
Tyk-2(K930I) (Fig. 1C, long and short exposures). Interest- 
ingly, tyrosine phosphorylation of the mutant Tyk-2 protein 
was detected when this mutant kinase was coexpressed with 
wild type Jak-l, suggesting that Jak-1 could be responsible for 
at least part of tyrosine phosphorylation f Tyk-2. The associ- 
ation of Tyk-2(K930I) with Jak-1 was also detected by im- 
munoblotting with anti-Tyk-2 and -Jak-1 antibodies (data not 
shown). These data clearly demonstrate that (i) there is an 
association between the Tyk-2 and Jak-1 tyrosine kinases, 
(ii) this interaction does not require tyrosine kinase activity of 
the Tyk-2 tyrosine kinase (Fig. 1C), and (iii) a similar interac- 
tion is likely to occur between Jak-1 and Jak-2 tyrosine kinases 
(Fig. 1B, right panel). The finding of tyrosine phosphorylation 
of the Tyk-2(K930I) mutant further supports the data obtained 
by genetic omplementation studies [9,22] which shows interde- 
pendence in the activation (tyrosine phosphorylation) of the 
Jak-1 and Tyk-2 kinases in IFN0~ signaling. However, the level 
of tyrosine phosphorylation of the Tyk-2(K930I) protein ob- 
served was lower than when Tyk-2 wild type is overexpressed 
alone suggesting that the Tyk-2 kinase may also undergo intra- 
molecular and/or intermolecular tyrosine phosphorylation (see 
below). 
3.3. Homodimerization f Tyk-2 
To test whether the Tyk-2 tyrosine kinase forms a homo- 
dimer, we coexpressed the wild type Tyk-2 kinase and a Tyk-2 
construct in which the whole kinase domain has been deleted 
(Tyk-2KD-). The anti-Tyk-2 rnAb raised against the N-termi- 
nal region of Tyk-2 recognizes both the wild type and the KD- 
forms of Tyk-2 (Fig. 2A, lanes 2, 4, 6, and 8). The rabbit serum 
raised against the C terminal part of Tyk-2, deleted in the KD- 
construct, only recognizes the wild type form (Fig. 2A, lane 6, 
compare blotting with anti-Tyk-2 C-terminal and anti-Tyk-2 
mAb). Fig. 2A (lower panel, blotting with Tyk-2 mAb) shows 
that the Tyk-2 C-terminal serum coprecipitates Tyk-2KD- with 
Tyk-2 wild type in cells cotransfected with wild type Tyk-2 and 
Tyk-2KD- constructs (lane 8), indicating that Tyk-2 forms a 
homodimer. Figure 2A (right side, upper and lower panels) also 
shows intense tyrosine phosphorylation of wild type Tyk-2 
when it is transfected alone (lanes 10 and 12); however, there 
is a decrease in tyrosine phosphorylation of wild type Tyk-2 
4-- 
Fig. 1. Interaction between the Jak-I and Tyk-2 kinases. (A) Hela cells were treated with 10,000 U/ml of IFNct2 for 10 min at 37°C or left untreated, 
lysed in lysis buffer (1% Triton X-100/ 150 mM NaCI/25 mM HEPES pH 7.5/1 mM EDTA/100/IM sodium orthovanadate/100 mM NaF, 1 mM 
MgCIJ1 mM phenyl methylsulfonyl fluoride/0.15 U/ml aprotinin, 10/lg/ml leupeptin), and immunoprecipitated with the anti-Jak-1 and -Jak-2 rabbit 
sera (UBI), or anti-Tyk-2 serum [8]. Immunoblotting was performed using anti-Jak-1 and -Tyk-2 monoclonal antibodies (Transduction Laboratories). 
The filter was stripped with 2% SDS/5% 2-mercaptoethanol/62.5 mM Tris pH 6.8 at 50°C for 30-60 min. Weak coprecipitation of Tyk-2 by the 
anti-Jak2 antibody was observed in some immunoblots and it could be explained by interaction of these Jak kinases in other cytokine systems [27]. 
(B) Overexpression f the Jak kinases using the vaccinia virus system. The cDNAs encoding the wild type Jak-1 and Tyk-2 tyrosine kinases and the 
kinase deficient mutant Tyk-2(K930I) were subcloned into the pGem vector under the control of the T7 promoter [24]. No IFN~ treatment was 
performed in the vaccinia virus experiments because vaccinia virus blocks binding and signaling through the type I IFN-R [26]. A weak tyrosine 
phosphorylated band observed in anti-Tyk-2 immunoprecipitates after transfection with Tyk-2(K930I) does not correspond to Tyk-2 since it isnot 
detected in anti-Tyk-2 immunoblots (data not shown). (C) Overexpression f Tyk-2(K930I) and wild type Jak-1. Coexpression of the Tyk-2(K930I) 
and wild type Jak-I was achieved as described in (B). Immunoblotting was performed with the anti-phosphotyrosine antibody 4G10 (UBI). 
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when it is cotransfected with the KD- mutant (lanes 14 and 16). 
This result could not be completely explained by lower levels 
of expression of Tyk-2 wild type in cotransfection experiments 
(see below). 
3.4. Homodimerization f Tyk-2 does not require kinase activity 
To examine whether ty osine kinase activity of Tyk-2 is nec- 
essary for homodimerization, wecoexpressed both kinase defi- 
cient forms of Tyk-2, Tyk-2KD- and Tyk-2(K930I), in COS 7 
cells. Fig. 2B shows that the kinase deficient forms can form 
a dimer (lane 6) indicating that tyrosine kinase activity and 
tyrosine phosphorylation are not required for dimerization. 
Interestingly, coexpression of Tyk-2KD- with wild type Jak-1 
did not result in an interaction between Tyk-2KD- and Jak-1 
(Fig. 2B) suggesting that the interaction between Tyk-2 and 
Jak-1 may require the tyrosine kinase domain of Tyk-2. 
3.5. Intermolecular tyrosine phosphorylation fthe Tyk-2 dimers 
We next determined whether the homodimer undergoes in- 
termolecular tyrosine phosphorylation by coexpressing wild 
type Tyk-2 and a Tyk-2(K930I) construct tagged with the HA 
epitope in 293T cells. When these constructs are cotransfected 
in a ratio of 3:1 (wt/mutant) specific tyrosine phosphorylation 
of Tyk-2(K930I) is observed (Fig. 2C, lane 2). Decreasing the 
ratio to 1:1 (lane 4) impaired tyrosine phosphorylation asex- 
pected when a larger number of Tyk-2(K930I) homodimers are 
formed. Similar results are observed when an anti-Tyk-2 serum 
was used for immunoprecipitation; however, the levels of tyro- 
sine phosphorylated Tyk-2 are higher due to detection of both 
wild type and K930I forms by the Tyk-2 serum (Fig. 2C, lower 
panel). These result demonstrates that the Tyk-2 homodimer 
undergoes intermolecular phosphorylation. More over, the 
lack of tyrosine phosphorylation f Tyk-2KD- in a Tyk-2KD-/ 
Tyk-2 wild type homodimer (Fig. 2A) also indicates that the 
tyrosine residue(s) that is (are) phosphorylated are in the kinase 
domain. 
The data presented here demonstrate that the Jak-1 and 
Tyk-2 tyrosine kinases interact constitutively and after IFNct 
treatment in Hela cells. This interaction does not require Tyk-2 
kinase activity, but may require the presence of the kinase 
domain of Tyk-2 since the Tyk-2KD- mutant failed to associate 
with Jak-l. Second, the Tyk-2 kinase is constitutively present 
as a homodimer with the ability of intermolecular tyrosine 
phosphorylation. The interaction between the Tyk-2 and Jak-1 
kinases plays a role in the assembly of the high affinity IFNc~R 
explaining the finding that mutant cells that lack either Tyk-2 
or Jak-1 bind IFNct with low affinity [9,23]. Altogether these 
data lead us to propose amodel in which activation of the IFNct 
system can be separated in different stages (Fig. 3). First, bind- 
ing of type I IFNs to the ~ and fl subunits leads to activation 
of the Tyk-2 and Jak-1 tyrosine kinases first by cross-phospho- 
rylation between the kinases followed by intermolecular phos- 
phorylation of the homodimers. This sequence of events is 
supported by genetic complementation studies [9] indicating 
that no phosphorylation is obtained when either Jak kinase is 
missing and by the data presented here (Fig. 1). The role of 
intermolecular phosphorylation f the homodimer is not clear, 
but it is possible that it serves as an amplification system which 
activates neighboring receptors. In a second stage, Tyk-2 and 
Jak-1 tyrosine phosphorylate he c~ and fl subunit of the recep- 
tor, respectively [7,8], and the Statl and Stat2 transcription 
factors. Our preliminary studies indicate that the Statl and 
Star2 factors are docked to the flL subunit in a ligand-independ- 
ent fashion forming a constitutive complex with the receptor 
and Jak kinases (Domanski et al., manuscript in preparation). 
Finally, a third stage would involve the formation of the 
ISGF3~ complex, translocation to the nucleus an activation of 
gene transcription. 
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Fig. 3. Model for activation of the IFNct system. The IFNc~R is represented by c~ and flL subunits. The -ryk-2 tyrosine kinase is shown forming a 
homodimer. This model also postulates that Jak-1 homodimerizes because of the similarities between the Jak- kinases. The Tyk-2 and Jak-1 kinases 
associate with each other and with the c~ and fl subunits, respectively. The transcriptional f ctors Statl and Stat2 are docked by the fl subunit (ilL) 
(Domanski et al., manuscript in preparation). The arrows indicate the crossphosphorylation of the Jak kinases and the intermolecular phosphorylation 
of the Jak homodimers. The model does not speculate on tyrosine phosphorylation f a particular Stat factor by a specific Jak kinase. 
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